Abstract:Currently, CAR-T cell therapy relies on an individualized manufacturing process in which patient's own T cells are infused back into patients after being engineered and expanded ex vivo. Despite the astonishing outcomes of autologous CAR-T cell therapy, this approach is endowed with several limitations and drawbacks, such as high cost and time-consuming manufacturing process. Switching the armature of CAR-T cell therapy from autologous settings to allogeneic can overcome several bottlenecks of the current approach. Nevertheless, the use of allogeneic CAR-T cells is limited by the risk of life-threatening GvHD. Thus, in recent years, developing a method to move CAR-T cell therapy to allogeneic settings without the risk of GvHD has become a hot research topic in this field. Since the alloreactivity of αβ T-cell receptor (TCR) accounts for developing GvHD, several efforts have been made to disrupt endogenous TCR of allogeneic CAR-T cells using gene editing tools to prevent GvHD. Nonetheless, the off-target activity of gene editing tools and their associated genotoxicities, as well as the negative consequences of endogenous TCR disruption, are the main concerns of using this approach. As an alternative, CAR αβ-T cells can be replaced with other types of CAR-engineered cells that are capable of recognizing and killing malignant cells through CAR while avoiding the induction of GvHD. These alternatives include T cell subsets with restricted TCR repertoire (γδ-T, iNKT, virus-specific T, double negative T cells, and MAIT cells), killer cells (NK and CIK cells), non-lymphocytic cells (neutrophils and macrophages), stem/progenitor cells, and cell-free extracellular vesicles. In this review, we discuss how these alternatives can move CAR-based immunotherapy to allogeneic settings to overcome the bottlenecks of autologous manner without the risk of GvHD. We comprehensively discuss the pros and cons of these alternatives over the traditional CAR αβ-T cells in light of their preclinical studies and clinical trials.

‘Off-the-shelf’ allogeneic CAR T cells: development and challenges

Allogeneic "Off-the-Shelf" CAR T cells: Challenges and advances

Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks

Toward “off‐the‐shelf” allogeneic CAR T cells

Allogeneic CAR-T Therapy Technologies: Has the Promise Been Met?

Current Perspectives on the Use of off the Shelf CAR-T/NK Cells for the Treatment of Cancer

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

Clinical Pharmacology Considerations for the “ Off‐the‐Shelf ” Allogeneic Cell Therapies

ReCARving the future: bridging CAR T-cell therapy gaps with synthetic biology, engineering, and economic insights

Fine-Tuning through Generations: Advances in Structure and Production of CAR-T Therapy

Strategies for Overcoming Bottlenecks in Allogeneic CAR-T Cell Therapy

Allogeneic chimeric antigen receptor T cells for children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia

Allogeneic CAR T Cells: Complex Cellular Therapy Designs Test the Limits of Our Preclinical Models

Strategies to Circumvent the Side-Effects of Immunotherapy Using Allogeneic CAR-T Cells and Boost Its Efficacy: Results of Recent Clinical Trials

Use of Cell and Genome Modification Technologies to Generate Improved “Off-the-Shelf” CAR T and CAR NK Cells

Recent updates on allogeneic CAR-T cells in hematological malignancies

Allogeneic CAR-T cells for cancer immunotherapy

Review: Sustainable Clinical Development of CAR-T Cells – Switching From Viral Transduction Towards CRISPR-Cas Gene Editing

[Current state and future prospects of off-the-shelf allogeneic CAR NK therapy]

Genetic engineering strategies to enhance antitumor reactivity and reduce alloreactivity for allogeneic cell-based cancer therapy

Potential alternatives to αβ-T cells to prevent graft-versus-host disease (GvHD) in allogeneic chimeric antigen receptor (CAR)-based cancer immunotherapy: A comprehensive review